223 related articles for article (PubMed ID: 12182908)
1. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
[TBL] [Abstract][Full Text] [Related]
2. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
3. Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities.
Husain SS
Biochemistry; 1991 Jun; 30(23):5797-805. PubMed ID: 1828371
[TBL] [Abstract][Full Text] [Related]
4. The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation.
Sun Z; Chen YH; Wang P; Zhang J; Gurewich V; Zhang P; Liu JN
Biochim Biophys Acta; 2002 Apr; 1596(2):182-92. PubMed ID: 12007600
[TBL] [Abstract][Full Text] [Related]
5. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity.
Lucas MA; Straight DL; Fretto LJ; McKee PA
J Biol Chem; 1983 Oct; 258(20):12171-7. PubMed ID: 6226655
[TBL] [Abstract][Full Text] [Related]
6. Domain-dependent action of urokinase on smooth muscle cell responses.
Tanski WJ; Fegley AJ; Roztocil E; Davies MG
J Vasc Surg; 2004 Jan; 39(1):214-22. PubMed ID: 14718842
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
8. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
9. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study.
Ellis V; Scully MF; Kakkar VV
J Biol Chem; 1987 Nov; 262(31):14998-5003. PubMed ID: 3667621
[TBL] [Abstract][Full Text] [Related]
11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
13. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis.
Ho-Tin-Noé B; Rojas G; Vranckx R; Lijnen HR; Anglés-Cano E
FEBS J; 2005 Jul; 272(13):3387-400. PubMed ID: 15978044
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells.
Kim KS; Hong YK; Joe YA; Lee Y; Shin JY; Park HE; Lee IH; Lee SY; Kang DK; Chang SI; Chung SI
J Biol Chem; 2003 Mar; 278(13):11449-56. PubMed ID: 12529357
[TBL] [Abstract][Full Text] [Related]
15. A battery of monoclonal antibodies that induce unique conformations to evolve cryptic but constitutive functions of plasminogen.
Madoiwa S; Arai K; Ueda Y; Ishizuka M; Mimuro J; Asakura S; Matsuda M; Sakata Y
J Biochem; 1997 Feb; 121(2):278-87. PubMed ID: 9089401
[TBL] [Abstract][Full Text] [Related]
16. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
17. Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase).
Pannell R; Gurewich V
Blood; 1987 Jan; 69(1):22-6. PubMed ID: 3790724
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
19. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
Okada SS; Grobmyer SR; Barnathan ES
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
[TBL] [Abstract][Full Text] [Related]
20. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
